Methods: We carried out a prospective, randomized, double blind controlled trial involving 63 consecutive consenting male patients admitted with diagnosis of uncomplicated alcohol withdrawal. The patients were randomized into two groupsbased on the type of lorazepam dosage: symptom-triggered (n = 33) and fixed tapering dose regimens (n = 30).